1. Scrip
  2. >>COVID-19

Shionogi Files Antiviral NDA In China, Eyes Wider Use

Competes with Pfizer's Paxlovid Upon Approval

 
• By Brian Yang

Undeterred by recent home turf setback, Japanese drug maker Shionogi rides a China’s policy tailwind and bets on Chinese approval for its antiviral COVID drug.

Doctor with Covid pill
SHIONOGI FILES CHINA NDA FOR ITS COVID PILL, EYES WIDER USE • Source: Shutterstock

Days after a surprise setback from its home country regulators, Shionogi & Co. Ltd.hopes a Chinese approval for its antiviral will help the Japanese drug maker in the second largest pharma market.

Partnered with Ping An, China’s major life insurance company, Shionogi has filed a new drug approval application with the China National Medical Products Administration for its COVID

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Trump’s MFN Executive Order More Rhetoric Than Action

 
• By Jessica Merrill

The details of Trump’s latest executive order on drug pricing are vague and the president put more blame on other countries and pharma distributors than drug companies.

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.